Will Rising Interest Rates Hurt Private Debt and Private Equity? It is hard to tell for sure because private investments are, by definition, private, and we don't have the same level of transparency that we have with publicly traded investments. However, with the 10-year Treasury crossing the 5% mark, common sense would tell you that higher interest rates could put even more strain on an already strained private debt and private equity market. Private equity funds frequently use leverage, meaning they borrow money to enhance potential returns. The typical holding period for a private equity investment is generally seven to 10 years, but an increase in interest rates raises the cost of borrowing for private equity firms, which can reduce profits and ultimately investor returns. Many private equity funds are already facing potential losses in software companies because of concerns that artificial intelligence could disrupt or even put some of these businesses out of business. Private equity firms may want to sell these investments quickly, but as interest rates rise, other investors may become less willing to take on additional risk because the risk-free return available from Treasury securities has become more attractive. The longer these private investments remain in a fund, the longer the fund may have to carry its debt and pay interest, which can further reduce investor returns. PitchBook estimated that the average private equity return in 2025 was around 7%, the lowest in 14 years, despite decent economic growth and relatively stable interest rates. For investors who own publicly traded private equity firms, the results have also been difficult. Companies ranging from Apollo Global Management to Blue Owl have seen significant declines in their stock prices year to date. If interest rates remain elevated, there could continue to be pressure on the business models of these firms. For private debt, the story is not necessarily better, even if your broker tells you that it is "stable." The same basic principle applies to private debt as it does to publicly traded bonds: when interest rates rise, the value of existing debt generally falls. With private debt, you may not see that decline reflected in a daily market price because the investments are not publicly traded. That does not mean the underlying economic impact isn't occurring. If a private debt fund eventually needs to sell assets, refinance debt, or deal with defaults, those underlying losses can become much more visible. One problem can potentially lead to another as lenders and borrowers are forced to deal with higher financing costs and declining asset values. At Wilsey Asset Management, we have been cautious about private equity and private debt for years. We understand why these investments are attractive and why brokers sell them, particularly because they can generate significant fees and commissions. However, we believe investors need to understand the risks, especially in an environment where interest rates remain elevated. One of the biggest concerns with private investments is liquidity. Unlike publicly traded stocks and bonds, investors in many private funds cannot simply sell their investment whenever they want. Withdrawals may be limited to certain periods, sometimes only once a quarter, and funds can impose additional restrictions when too many investors try to withdraw money at the same time. If interest rates remain high for an extended period, the combination of higher borrowing costs, lower valuations, weaker exit opportunities and limited liquidity could create a difficult environment for private equity and private debt investors. The fact that you don't see the losses on a daily statement doesn't necessarily mean the risk isn't there. Is the New Siri AI Already Obsolete? Is it possible that Apple’s latest update to its famous Siri has already turned it into a follower rather than a leader? The new Siri AI assistant is supposed to be able to do things like book travel plans, fill out online forms, cancel appointments, and even file complaints with customer service. But in today’s fast-moving world of technology, there are already services out there, like Instinct, and Meta has built a new AI platform called Muse that runs in the AI cloud, meaning you don’t necessarily need to be inside a specific app to use it. Many of these services can connect to your Gmail account and communicate with your iMessage or WhatsApp. Instinct and Muse can go beyond simply setting appointments. They can look at your existing appointments, identify conflicting travel arrangements, and then cancel the conflict and rebook the necessary reservations for you. They can also look for reliable restaurant recommendations nearby and book a reservation for you without you having to do much of anything. With Instinct, it can even create an account on a website, navigate the site, find locations and times for events being promoted, and add those events to your calendar for you. Currently, Siri AI can’t freely surf websites and is largely limited to working through apps on the iPhone. If services like Instinct and Muse are able to outperform Siri while Apple continues to keep its AI experience primarily within the iPhone ecosystem, users could eventually start asking themselves why they need to pay such a high price for Apple’s newest phones when cheaper Android phones may offer access to more capable AI assistants. Apple has built its reputation on being a technology leader. The question is whether Siri will remain one. Would you trust Facebook with your personal and financial information? This is an important question because this is the direction AI appears to be heading. Meta, which owns Facebook, recently released its new AI agent, Muse, and to complete tasks and make life easier for you, it will need deep access to your personal information. Within the first five days of its release, Muse was downloaded 600,000 times, which on the surface sounds like a lot. However, keep in mind that there are roughly 3.6 billion users across Meta’s platforms, which makes 600,000 downloads sound like a very small number. The bigger question is: Do we trust Mark Zuckerberg and Meta with privileged information based on the company’s track record? Yes, they use words that sound good when describing Muse, such as “safe,” “secure,” and “private.” They also say Muse will run on a digitally walled-off virtual machine that other agents cannot access. OK, that sounds good, but let’s look at the track record. Six years ago, Meta agreed to pay a $5 billion fine to the FTC over user privacy violations related to what became known as the Cambridge Analytica scandal. About a year later, information belonging to 533 million users was leaked. Then, in 2023, the company was hit with a record $1.3 billion fine related to the transfer of European users’ data to U.S. servers. Still fresh in our minds is the recent $18 billion settlement involving allegations that Meta harmed teenagers. The cost of using Muse could be as much as $100 per month, depending on how much you use it. If you only have light usage, it could be free. When you register for Muse, a warning pops up saying, “May make mistakes or take unexpected actions, so review all its work.” All I can say to that is: Wow! If this is how companies are going to make money from AI, by gaining access to all of your personal information so they can set appointments, send emails, manage your finances, pay bills, and handle other things that make your life easier, I’ll just say no thank you. I’ll do it myself. How about you? Would you trust an AI agent with that much access to your personal and financial information? Lawsuits are starting to form against the makers of GLP-1 drugs It’s no surprise to me that there are concerns about potential side effects from the popular weight-loss drugs known as GLP-1s. At this point, the potential connection between these drugs and certain vision problems is still being investigated, but there are some developments that investors and patients should be aware of. The concern involves a condition known as NAION, or non-arteritic anterior ischemic optic neuropathy, which can cause sudden vision loss. In Denmark, where drug company Novo Nordisk is headquartered, 27 patients on the diet drugs were awarded as much as $1.5 million due to NAION and there are still 38 more pending cases in the country. There are also now warning labels on the drugs in the UK, Japan, and Australia. The FDA in the United States is currently reviewing the concerns but at this time are not placing a warning label on the drugs. European regulators have concluded that NAION is a very rare side effect of semaglutide, affecting about 2 in 10,000 people. Unfortunately, it appears this side effect can occur even after taking the drug for just 6 to 12 months. They have recommended that patients experiencing sudden or rapidly worsening vision seek medical attention immediately, and that treatment be stopped if NAION is confirmed. The risk appears to be very small, but when you are talking about potentially permanent vision loss, even a rare side effect deserves attention. For someone taking these medications for diabetes or significant obesity-related health risks, the potential benefits may be an important part of the risk-benefit discussion with their doctor. But for someone simply looking to lose 10 or 20 pounds, I think it is reasonable to ask whether the potential risks are worth it. Ask yourself this question: If you lost your vision, what would you be willing to pay to get it back? From an investment standpoint, this is also something I would be watching closely. If lawsuits continue to build and regulators impose additional warnings or restrictions, it c